Program
ARQ-154
A development code. Also written as “ARQ-154 Foam 0.3%”, “Roflumilast Foam” and “Roflumilast Foam 0.3%”.
Its studies are mostly in Dermatitis, Seborrheic · Psoriasis, led by Arcutis Biotherapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Arcutis Biotherapeutics | 50 open or running | phase 3since Jul 13, 2021 | Sep 13, 2019 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2019First study: phase 2 study in Dermatitis, SeborrheicFirst studyNCT04091646 · 226 enrolled · United States, Canada
- Oct 14, 2019Phase 2 study in Plaque PsoriasisNCT04128007 · 304 enrolled · United States, Australia, Bulgaria and more
- Jun 22, 2020Phase 2 study in Dermatitis, SeborrheicNCT04445987 · 408 enrolled · United States
- Jul 13, 2021Phase 3 study in Dermatitis, SeborrheicNCT04973228 · 457 enrolled · United States, Canada
- Dec 19, 2025Phase 1 study in PsoriasisNCT07340216 · 22 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07340216Psoriasis · United States | 1 | Completed | Apr 30, 2026 | 22 |
| NCT04973228Dermatitis, Seborrheic · United States, Canada | 3 | Completed | Apr 6, 2022 | 457 |
| NCT04445987Dermatitis, Seborrheic · United States | 2 | Completed | Nov 19, 2022 | 408 |
| NCT04128007Plaque Psoriasis · United States, Australia, Bulgaria and more | 2 | Completed | Sep 23, 2020 | 304 |
| NCT04091646Dermatitis, Seborrheic · United States, Canada | 2 | Completed | Aug 18, 2020 | 226 |
How it is read
Names in the registry
- “ARQ-154 Foam 0.3%”, 1 entry
- “ARQ-154”, 1 entry
- “Roflumilast Foam”, 1 entry
- “Roflumilast Foam 0.3%”, 1 entry
- “Roflumilast foam 0.3%”, 1 entry
Codes read as this program: ARQ154.
Conditions, from the studies’ own filings
- Dermatitis, Seborrheic, 3 studies
- Psoriasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.